Celonic Group Leverages Merck’s Breez™ Micro-Bioreactor Platform, Enabling Next-Generation Perfusion-Based Bioprocessing.
- Celonic Group leverages Merck’s Breez™ micro-bioreactor technology to optimize bioprocessing efficiency and scalability.
- This technology integration supports Celonic’s efforts to enhance expertise in monoclonal antibody (mAb) development and manufacturing through advanced Next-Generation Technologies.
- Celonic’s streamlined production, enabled by Merck’s technology, sets new standards in reducing the cost of goods per gram for biologics.
Basel, Switzerland, 12 March 2025 – Celonic Group, a Swiss-Based Quality contract development and manufacturing organization (CDMO), has announced that it is integrating Merck’s Breez™ micro-bioreactor platform into its process development. This addition will further enhance Celonic’s capabilities in monoclonal antibody (mAb) development and manufacturing by enabling highly efficient, scalable perfusion-based bioprocessing from early-stage development to large-scale manufacturing.
The Breez™ 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture system. By incorporating Breez™ into its process development, Celonic aims to accelerate upstream process optimization while reducing cost of goods per gram and increasing operational efficiency.
“This technology integration marks a significant milestone in our pursuit of innovative bioprocessing solutions,” said Samanta Cimitan Ph.D., CEO of Celonic Group. “By leveraging the Breez™ platform, we can enhance our ability to develop and manufacture biologics with the aim of increasing productivity, reducing the cost of goods per gram ultimately benefiting our clients and patients worldwide.”
About Celonic:
Celonic is a “Pure Play” Biologics Contract Development Manufacturing Organization (CDMO) with significant expertise in cell culture technologies, process development and manufacturing of recombinant proteins. Celonic’s roots trace back to 1982 as a spin-off of the Max Planck Institute in Germany. Today Celonic has a state-of-the-art Biologics Development and Innovation Center in Basel, Switzerland (Headquarters), and GMP manufacturing facilities in Heidelberg, Germany. This facility is equipped to handle complex biologics and bioprocessing technologies including fed-batch, N-1 perfusion and full perfusion production processes. At present, more than 500 highly qualified employees work at Celonic across the two locations.
Celonic Group Contact Details
Elisa Witt
Marketing and Communications Manager
Elisa.Witt@celonic.com
M: +41 76 588 67 59
